Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate CancerActive Not Recruiting
NCT01957436Phase 3Updated Nov 12, 2024
Sponsor: UNICANCER
Metastatic Prostate Cancer
Belgium, France, Ireland, Italy, Romania +2 more
Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase DeficiencyCompleted
NCT02004691Phase 2, Phase 3Updated Nov 7, 2024
Sponsor: Genzyme, a Sanofi Company
Sphingomyelin Lipidosis
United States, Argentina, Australia, Belgium, Brazil +12 more
MInimal Residual Disease Adapted StrategyActive Not Recruiting
NCT04934475Phase 3Updated Nov 7, 2024
Sponsor: Intergroupe Francophone du Myelome
Multiple Myeloma
Belgium, France, Reunion
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological MalignanciesCompleted
NCT01084252Phase 1, Phase 2Updated Nov 1, 2024
Sponsor: Sanofi
Hematological Malignancy
United States, Argentina, Belgium, Brazil, Chile +12 more
A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical IllnessTerminated
NCT05819112N/AUpdated Oct 30, 2024
Sponsor: Sanofi
Venous Thromboembolism
United States
Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With EnoxaparinTerminated
NCT05819125N/AUpdated Oct 29, 2024
Sponsor: Sanofi
Venous Thromboembolism
United States
Isatuximab and Bendamustine in Systemic Light Chain AmyloidosisWithdrawn
NCT04943302Phase 2Updated Oct 18, 2024
Sponsor: Tufts Medical Center
Amyloidosis · Light Chain (AL) Amyloidosis
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the USCompleted
NCT03537508Phase 3Updated Oct 15, 2024
Sponsor: Sanofi Pasteur, a Sanofi Company
Healthy Volunteers (Meningococcal Infection)
United States, Puerto Rico
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)Completed
NCT02776735Phase 2Updated Oct 15, 2024
Sponsor: Sanofi
Juvenile Idiopathic Arthritis
United States, Argentina, Canada, Chile, Czechia +10 more
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)Completed
NCT02914886Phase 4Updated Oct 15, 2024
Sponsor: Kinderkrankenhaus auf der Bult
Type 1 Diabetes · Lipoatrophy
Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine UptakeCompleted
NCT05542004NAUpdated Oct 10, 2024
Sponsor: Tor Biering-Sørensen
Influenza · Behavior and Behavior Mechanisms
Denmark
Register Schweres Asthma - German Asthma Net e.V.Recruiting
NCT06035289N/AUpdated Oct 2, 2024
Sponsor: German Asthma Net e.V.
Severe Asthma
Germany
Seasonal Influenza Vaccine Effectiveness Study in KenyaCompleted
NCT01432340N/AUpdated Sep 20, 2024
Sponsor: Gideon Emukule
Influenza · Influenza Like Illness · Severe Acute Respiratory Illness
Kenya
Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled SyringeCompleted
NCT06114238Phase 1Updated Sep 19, 2024
Sponsor: Sanofi
Chronic Obstructive Pulmonary Disease
United States
Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry PatientsCompleted
NCT02023086N/AUpdated Sep 19, 2024
Sponsor: Université de Montréal
Fabry Disease
Canada
Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and ToddlersCompleted
NCT05964582N/AUpdated Sep 19, 2024
Sponsor: Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Infections
United States, Finland, Ghana, Honduras, India +2 more
Immunological Mechanisms Underlying Mucosal IgE ResponsesRecruiting
NCT06234761N/AUpdated Sep 19, 2024
Sponsor: University Hospital, Ghent
Pathophysiology
Belgium
Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue VaccineCompleted
NCT02948933N/AUpdated Sep 19, 2024
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Fever · Dengue Hemorrhagic Fever
A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults SubjectsCompleted
NCT05846009Phase 1Updated Aug 27, 2024
Sponsor: Sanofi
Osteochondrodysplasia
United States
Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)Completed
NCT00708981NAUpdated Aug 26, 2024
Sponsor: Cook County Health
Diabetic Nephropathy
United States
Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS PatientsRecruiting
NCT06567418N/AUpdated Aug 22, 2024
Sponsor: Yun Dai Chen
Acute Coronary Syndrome
China
Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune ModulationRecruiting
NCT05098821N/AUpdated Aug 21, 2024
Sponsor: Charite University, Berlin, Germany
Atopic Dermatitis
Germany
Primary Operation in SYnchronous meTastasized InVasivE Breast CancerCompleted
NCT01015625NAUpdated Aug 19, 2024
Sponsor: Austrian Breast & Colorectal Cancer Study Group
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Austria
Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With PolypsNot Yet Recruiting
NCT06556264Phase 4Updated Aug 16, 2024
Sponsor: Dr. Andrew Thamboo, MD
Chronic Rhinosinusitis With Nasal Polyps · Asthma
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid TumorsCompleted
NCT03192345Phase 1Updated Aug 7, 2024
Sponsor: Sanofi
Malignant Solid Tumor
United States, Australia, Belgium, Canada, Estonia +8 more

Previous page Next page